MXPA06003533A - Composicion farmaceutica que comprende acido (2r)-2-propiloctanoico como un ingrediente activo. - Google Patents

Composicion farmaceutica que comprende acido (2r)-2-propiloctanoico como un ingrediente activo.

Info

Publication number
MXPA06003533A
MXPA06003533A MXPA06003533A MXPA06003533A MXPA06003533A MX PA06003533 A MXPA06003533 A MX PA06003533A MX PA06003533 A MXPA06003533 A MX PA06003533A MX PA06003533 A MXPA06003533 A MX PA06003533A MX PA06003533 A MXPA06003533 A MX PA06003533A
Authority
MX
Mexico
Prior art keywords
drug containing
active ingredient
acid
propyloctanoic acid
salt
Prior art date
Application number
MXPA06003533A
Other languages
English (en)
Inventor
Seiichi Tanikawa
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MXPA06003533A publication Critical patent/MXPA06003533A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Details Of Rigid Or Semi-Rigid Containers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere a un farmaco el cual es util para enfermedades neurodegenerativas, el cual comprende de aproximadamente 1 a aproximadamente 5 equivalentes de un ion metalico basico tomando como referencia 1 equivalente de acido (2R)-2-propiloctanoico o una sal del mismo, el cual se suministra a partir de una sal metalica de acido debil o un hidroxido metalico, y opcionalmente comprende adicionalmente un aditivo. El farmaco de la presente invencion tiene un pH el cual es adecuado para administracion intravenosa, es resistente a fluctuaciones del pH y no se enturbia cuando se disuelve en una infusion, y una inyeccion y similar se puede preparar a partir de ahi usando cualquier liquido disolvente y/o liquido de dilucion.
MXPA06003533A 2003-10-03 2004-10-01 Composicion farmaceutica que comprende acido (2r)-2-propiloctanoico como un ingrediente activo. MXPA06003533A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003345124 2003-10-03
PCT/JP2004/014892 WO2005032536A1 (ja) 2003-10-03 2004-10-01 (２ｒ)−２−プロピルオクタン酸を有効成分とする薬剤

Publications (1)

Publication Number Publication Date
MXPA06003533A true MXPA06003533A (es) 2006-06-08

Family

ID=34419441

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06003533A MXPA06003533A (es) 2003-10-03 2004-10-01 Composicion farmaceutica que comprende acido (2r)-2-propiloctanoico como un ingrediente activo.

Country Status (21)

Country Link
US (1) US8053599B2 (es)
EP (1) EP1669065B1 (es)
JP (1) JP4715515B2 (es)
KR (1) KR101144553B1 (es)
CN (1) CN1889942B (es)
AU (1) AU2004277826B2 (es)
BR (1) BRPI0415001A (es)
CA (1) CA2540670A1 (es)
EC (1) ECSP066477A (es)
ES (1) ES2390055T3 (es)
IL (1) IL174655A0 (es)
IS (1) IS8430A (es)
MA (1) MA28142A1 (es)
MX (1) MXPA06003533A (es)
NO (1) NO20061460L (es)
NZ (1) NZ546231A (es)
RU (1) RU2388467C2 (es)
SG (1) SG146687A1 (es)
TW (1) TW200519080A (es)
WO (1) WO2005032536A1 (es)
ZA (1) ZA200602690B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200613009A (en) * 2004-06-11 2006-05-01 Ono Pharmaceutical Co Capsule having chewing stability
TWI462745B (zh) * 2005-04-28 2014-12-01 Takeda Pharmaceutical 安定的乳化組成物
JP5541845B2 (ja) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 アトピー性皮膚炎治療剤
AU2009312235B2 (en) * 2008-11-04 2014-01-16 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone
CA2734284C (en) 2008-11-20 2014-01-21 Techno Guard Co., Ltd. Pyrazolone derivative formulations
JP5759804B2 (ja) * 2011-06-27 2015-08-05 富士フイルム株式会社 容器詰製剤
JP2018052861A (ja) * 2016-09-29 2018-04-05 ノーベルファーマ株式会社 ホスフェニトインナトリウム注射剤
WO2020128928A1 (en) * 2018-12-19 2020-06-25 Jafari Javid Mihan A formulation for treatment of neurodegenerative and demyelinating and neuropathic disorders and a method for preparation thereof
CN110441421B (zh) * 2019-08-02 2022-09-09 聊城高新生物技术有限公司 一种高效液相色谱法测定恩他卡朋片溶出度的方法
CN112180095B (zh) * 2020-06-04 2023-10-13 三诺生物传感股份有限公司 一种心脑血管和糖尿病相关四高指标复合质控品及其制备方法
IT202000015895A1 (it) * 2020-07-27 2022-01-27 Univ Cattolica Del Sacro Cuore L’impiego di acido arundico nella terapia della sclerosi multipla
AU2022280595A1 (en) * 2021-05-26 2023-11-09 Daewoong Pharmaceutical Co., Ltd. Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
CN113341019A (zh) * 2021-06-09 2021-09-03 江西省药品检验检测研究院 一种乳酸左氧氟沙星氯化钠注射液中依地酸盐的分析方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2113574T3 (es) * 1993-06-01 1998-05-01 Ono Pharmaceutical Co Derivados del acido pentanoico.
JPH0782146A (ja) * 1993-07-23 1995-03-28 Sagami Chem Res Center 抗痴呆薬
JPH07285911A (ja) * 1994-04-20 1995-10-31 New Japan Chem Co Ltd 脂肪族モノカルボン酸組成物
JPH0853351A (ja) * 1994-08-11 1996-02-27 Sagami Chem Res Center 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤
JP3032447B2 (ja) * 1995-04-24 2000-04-17 小野薬品工業株式会社 光学活性な２−プロピルオクタン酸の製造方法
JP3084345B2 (ja) * 1995-04-26 2000-09-04 小野薬品工業株式会社 光学活性な２−プロピルオクタン酸の製造方法
JPH10298072A (ja) 1997-04-17 1998-11-10 Panacea Biotec Ltd 非ステロイド性抗炎症剤の遷移金属錯体
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
TWI268921B (en) * 1999-02-18 2006-12-21 Ono Pharmaceutical Co A process for preparing (2R)-2-propyloctanoic acid
US6552082B2 (en) * 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
KR100759771B1 (ko) * 2000-07-18 2007-10-04 오노 야꾸힝 고교 가부시키가이샤 성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제
JP4706950B2 (ja) * 2000-07-18 2011-06-22 小野薬品工業株式会社 アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤
JP4178405B2 (ja) * 2001-07-18 2008-11-12 小野薬品工業株式会社 脳虚血疾患治療剤

Also Published As

Publication number Publication date
TW200519080A (en) 2005-06-16
CA2540670A1 (en) 2005-04-14
NZ546231A (en) 2009-09-25
ECSP066477A (es) 2007-03-29
US8053599B2 (en) 2011-11-08
NO20061460L (no) 2006-07-03
AU2004277826B2 (en) 2010-05-27
WO2005032536A1 (ja) 2005-04-14
EP1669065A1 (en) 2006-06-14
EP1669065A4 (en) 2009-12-16
JPWO2005032536A1 (ja) 2006-12-14
US20070105956A1 (en) 2007-05-10
SG146687A1 (en) 2008-10-30
EP1669065B1 (en) 2012-07-18
KR101144553B1 (ko) 2012-05-11
KR20060099525A (ko) 2006-09-19
RU2388467C2 (ru) 2010-05-10
MA28142A1 (fr) 2006-09-01
IL174655A0 (en) 2006-08-20
ES2390055T3 (es) 2012-11-06
CN1889942B (zh) 2010-12-15
BRPI0415001A (pt) 2006-11-07
AU2004277826A1 (en) 2005-04-14
IS8430A (is) 2006-04-26
RU2006114835A (ru) 2007-11-20
ZA200602690B (en) 2007-07-25
CN1889942A (zh) 2007-01-03
JP4715515B2 (ja) 2011-07-06

Similar Documents

Publication Publication Date Title
ECSP066477A (es) Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo
EP4233861A3 (en) Compositions for treatment of essential tremor
MY188825A (en) High-concentration monoclonal antibody formulations
Djamshidian et al. Apomorphine and levodopa in Parkinson's disease: two revolutionary drugs from the 1950's
MX344727B (es) Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
EA200700389A1 (ru) Стабильный при хранении инфузионный раствор дигидроптеридинонов
JP2016539921A5 (es)
EA201270167A1 (ru) Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения
WO2008009476A3 (de) Konzentrierte methotrexat-lösungen
JP2014510067A5 (es)
WO2018089328A8 (en) TREATMENT OF CNS DISEASES USING GCS STIMULATORS
BRPI0519209A2 (pt) compostos orgçnicos
NZ702342A (en) Pharmaceutical formulation
HRP20200704T1 (hr) Vodena formulacija koja sadrži paracetamol i ibuprofen
ATE539761T1 (de) Mittel für injektionszwecke mit einem antibiotikum und das mittel enthaltende lösung zur injektion
ECSP066476A (es) Preparación de una infusión que comprende ácido (2r)-2-propiloctanoico como ingrediente activo
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
MY136546A (en) A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component
UA84578C2 (ru) Лекарственное средство, содержащее (2r)-2-пропилоктановую кислоту в качестве активного ингредиента
RU2012129115A (ru) Способ лечения острых послеродовых эндометритов у коров
RU2013148799A (ru) Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта
PH12017501005A1 (en) Injectable formulations of paracetamol
AR049015A1 (es) Composicion farmaceutica que comprende acido (2r)-2-propiloctanoico como un ingrediente activo
RU2008140019A (ru) Способ лечения и профилактики эндометритов у коров
UA120764U (uk) Лікарський препарат знеболювальної та спазмолітичної дії "фентаніл"

Legal Events

Date Code Title Description
FA Abandonment or withdrawal